Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_218_библиотеки_им_акад_М_И_Перельмана
.pdf
141
Список литературы
67. Федорова И.В. Клинико-патогенетические особенности артериальной ги-
пертонии при хронической обструктивной болезни легких. Дис. ... канд. мед.
наук. М., 2008.
68.
Федорова Т.А., Химочко Т.Г., Ройтман А.П. идр. К вопросу о состоянии ре-
нин-ангиотензин-альдостероновой системы у больных хроническими об-
структивными болезнями легких с легочным сердцем // Московский мед.
журн. 2001. № 1. С. 23–25.
69. Чазова И.Е., Блинова Н.В., Невзорова В.А. и др. Консенсус экспертов Рос-
сийского медицинского общества по артериальной гипертонии: артери-
альная гипертония и COVID-19 // Системные гипертензии. 2020. Т.17. №3.
C. 35-41.
70. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекоменда-
ции. Диагностика илечение артериальной гипертонии // Системные гипер-
тензии. 2019. Т. 16, № 1. С. 6–31.
71. Чазова И.Е., Лазарева Н.В., Ощепкова Е.В. Артериальная гипертония ихро-
ническая обструктивная болезнь легких: клиническая характеристика и эф-
фективность лечения (по данным Национального регистра артериальной
гипертонии) // Терапевтический архив. 2019. Т. 91, № 3. С. 4–10.
72. Чазова И.Е., Невзорова В.А., Амбатьелло Л.Г. идр. Клинические рекомендации
по диагностике илечению пациентов с артериальной гипертонией ихрони-
ческой обструктивной болезнью легких // Системные гипертензии. 2020; Т. 17,
№ 3. С. 7-34.
73. Чазова И.Е., Чучалин А.Г., Зыков К.А. идр. Диагностика илечение пациентов
с артериальной гипертонией ихронической обструктивной болезнью легких
(Рекомендации Российского медицинского общества по артериальной гипер-
тонии иРоссийского респираторного общества) // Системные гипертензии.
2013. Т. 10, № 1. С. 5–34.
74. Чевплянская О.Н., Дударев М.В., Мельников А.В. Продольная деформация
левого желудочка исостояние коронарного кровотока у пациентов с высо-
ким нормальным артериальным давлением // Артериальная гипертензия.
2016. Т.22, №. 3. С. 282-290.
75. Черток В.М., Захарчук Н.В., Черток А.Г. Клеточно-молекулярные механизмы
регуляции ангиогенеза в головном мозге // Журнал неврологии ипсихиатрии
им. С.С. Корсакова. 2017. Т. 117, № 8(2). С. 43-55.
76. Черток В.М., Невзорова В.А., Савченко А.К. идр. Возрастные особенности
организации микроциркуляторного русла бульбарной конъюнктивы // Тихо-
океанский медицинский журнал. 2020. № 3 (81). С. 57–61.
https://t.me/med1917
142
Список литературы
77. Aaron C. P., Schwartz J. E., Bielinski S. J. et al. Intercellular adhesion molecule 1 and
progression of percent emphysema: the MESA Lung Study // Respir. Med. 2015. Vol.
109, № 2. P. 255–264.
78.
Adams S., Luther M. Antibiotics are associated with lower relapse rates in
outpatientswith acute exacerbations of chronic obstructive pulmonary disease //
Chest. 2000. Vol. 117. P. 1345–1352.
79.
Adeloye D., Chua S., Lee C. et al. Global Health Epidemiology Reference Group
(GHERG). Global and regional estimates of COPD prevalence: Systematic review
and meta-analysis // J Glob Health. 2015. Vol. 5(2):020415.
80. Adnot S., Samoyeau R., Weitzenblum E. Treatment of pulmonary hypertension in
patients with chronic obstructive pulmonary disease: position of vasodilators with
special focus on urapidil // Blood Press Suppl. 1995. Vol. 3. P. 47–57.
81. Aguib Y., Suwaidi J.A. e Copenhagen City Heart Study (Østerbroundersøgelsen) //
Glob Cardiol Sci Pract. 2015. Vol. (3):33.
82.
Aksenova T.A., Gorbunov V.V., Tsarenok S.Y. Pulse wave velocity and other
indicators of arterial stiness in hypertension comorbidity and chronic obstructive
pulmonary disease // erapeutic Archive. 2018. Vol. 90, N 3. P. 10–15.
83. Albert R.K., Connett J., Bailey W.C. et al. Azithromycin for prevention of
exacerbations of COPD // N Engl J Med. 2011. Vol. 365. P. 689–698.
84.
Alison J.A., McKeough Z.J., Johnston K. et al. Australian and New Zealand
Pulmonary Rehabilitation Guidelines // Respirology. 2017. Vol. 22, N. 4. P. 800–819.
85.
Alkhathami M.G., Advani S.M., Abalkhail A.A. et al. Prevalence and mortality of
lung comorbidities among patients with COVID-19: A systematic review and meta-
analysis // Lung India. 2021. Vol. 38. S31-S40.
86. Allen C. L., Bayraktutan U. Risk factors for ischaemic stroke // Int. J. Stroke. 2008.
Vol. 3, № 2. P. 105–116.
87. Alqahtani J.S., Oyelade T., Aldhahir A.M. et al. Prevalence, Severity and Mortality
Associated with COPD and Smoking in Patients with COVID-19: A Rapid
Systematic Review and Meta-Analysis // PLoS One. 2020. Vol. 15, N. 5. e0233147.
88. Andreas S., Herrmann-Lingen C., Raupach T. et al. Angiotensin II blockers in
obstructive pulmonary disease: a randomised controlled trial // Eur Respir J. 2006.
Vol. 27, 5. P. 972–979.
89. Antyn A., Guell R., Gymes J. et al. Predicting the result of noninvasive ventilation in
severe acute exacerbations of patients with chronic airow limitation // Chest. 2000.
Vol. 117, N. 3. P. 828–833.
90. Arciniegas E., Frid M.G., Douglas I.S. et al. Perspectives on endothelial-to-mesenchymal
transition: Potential contribution to vascular remodeling in chronic pulmonary
hypertension // Am J Physiol Lung Cell Mol Physiol. 2007. N. 293. L. 1-8.
https://t.me/med1917
143
Список литературы
91. Appleton S., Jones T., Poole P. et al. Ipratropium bromide versus long-acting beta-2
agonists for stable chronic obstructive pulmonary disease // Cochrane Database
Syst Rev. 2006. Vol. 3. CD006101.
92.
Appleton S., Jones T., Poole P. et al. Ipratropium bromide versus short acting beta-2
agonists for stable chronic obstructive pulmonary disease // Cochrane Database
Syst Rev. 2006. Vol. 2. CD001387.
93.
Arnold N., T. Gori T., Schnabel R.B. et al. Relation between Arterial Stiness and
Markers of Inammation and Hemostasis – Data from the Population-based
Gutenberg Health Study // Scientic Reports. 2017. Vol.7. Р. 6346.
94. Arteriograph TensioClinic and its program TensioClinic. User’s manual. Early
diagnosis of arteriosclerosis. http://www.tensiomed.com/eng/tclin.
95.
Asanuma K., Magid R., Johnson C. et al. Uniaxial strain upregulates matrix-
degrading enzymes produced by human vascular smooth muscle cells // Am. J.
Physiol. Heart Circ. Physiology. 2003. Vol. 284, № 5. P. H1778–H1784.
96. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the
risk of acute coronary events based on the 10-year follow-up of the prospective
cardiovascular Münster (PROCAM) study // Circulation. 2002. Vol. 105. № 3. Р.
310-315.
97. Austin M.A., Wills K.E., Blizzard L. et al. Eect of high ow oxygen on mortality in
chronic obstructive pulmonary disease patients in prehospital setting: randomized
controlled trial // BMJ. 2010. Vol. 341. c5462.
98. Bafadhel M., McKenna S., Terry S. et al. Blood eosinophils to direct corticosteroid
treatment of exacerbations of chronic obstructive pulmonary disease: a randomized
placebo-controlled trial // Am J Respir Crit Care Med. 2012. Vol. 186, N. 1. P. 48–55.
99. Baker A.B., Edwards D., Murphy G. Metalloproteinase inhibitors: biological actions
and therapeutic opportunities // J. Cell Science. 2002. Vol. 115, Pt. 19. P. 3719–3727.
100. Balaban R.S., Nemoto S., Finkel T. Mitochondria, oxidants, and aging // Cell. 2005.
N. 120. P. 483–495.
101. Barbera J.A., Blanco I. Pulmonary hypertension in patients with chronic obstructive
pulmonary disease: advancesin pathophysiology and management // Drugs. 2009.
Vol. 69. P. 1153–1171.
102. Barnes P.J. eophylline // Am J Respir Crit Care Med. 2013. Vol. 188. P. 901–906.
103. Barnoya J., Glantz S.A. Cardiovascular Eects of Secondhand Smoke: Nearly as
Large as Smoking // Circulation. 2005. №. 111. Р. 2684- 2698.
104. Barreiro E., Peinado V. I., Galdiz J. B. et al. ENIGMA in COPD Project. Cigarette
smoke-induced oxidative stress: a role in chronic obstructive pulmonary disease
skeletal muscle dysfunctio // Am J Respir Crit Care Med. 2010. Vol. 182, № 4.
P. 477–488.
https://t.me/med1917
144
Список литературы
105. Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149
versus single bronchodilator therapy: the SHINE study // Eur Respir J. 2013.
Vol. 42. P. 1484–1494.
106.
Batura-Gabryel H., Grabicki M. Przewlekła obturacyjna choroba płuc i choroby
sercowo-naczyniowe--”kontinuum sercowo-płucne” [Chronic obstructive
pulmonary disease and cardiovascular diseases--’cardiopulmonary continuum’] //
Pneumonol Alergol Pol. 2014. Vol. 82, N 6. P. 590-596.
107. Baumbach G.L., Heistadn D.D. Remodeling of cerebral arterioles in chronic
hypertension // Hypertension. 1989. № 13. Р. 968-972.
108.
Bear R., Goldstein M., Phillipson E. et al. Eect of metabolic alkalosis on respiratory
function in patients with chronic obstructive lung disease // Can Med Assoc J. 1977.
Vol. 117, N. 8. P. 900–903.
109. Beard J.R., Ocer A.M., Cassels A.K. e World Report on Ageing and Health //
Gerontologist. 2016. Vol. 56. Suppl 2. S. 163-166.
110.
Beeh K.M., Westerman J., Kirsten A.M. et al. e 24-h lung-function prole of once-
daily tiotropium and olodaterol xed-dose combination in chronic obstructive
pulmonary disease // Pulm Pharmacol er. 2015. Vol. 32. P. 53–59.
111. Benowitz N. L. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease,
and erapeutics // Annu Rev PharmacolToxicol. 2009. Vol. 49. P. 57–71.
112.
Bergholdt H., Bathum L., Kvetny J et al. Study design, participation and
characteristics of the Danish General Suburban Population Study // Dan Med J.
2013 Vol. 60(9):A4693.
113.
Berrington de Gonzalez A., Hartge P., Cerhan J.R. et al. Body-massindex and
mortality among 1.46 million white adults // N Engl J Med. 2010. Vol. 363. P. 2211–
2219.
114. Bhatt S.P., Cole A.G., Wells J.M. et al. Determinants of arterial stiness in COPD //
BMC Pulm Med. 2014. Vol. 14 (1).
115. Bhatt S.P., Dranseld M.T. Chronic obstructive pulmonary disease and
cardiovascular disease // Transl Res. 2013. Vol. 162, N 4. P. 237–251.
116. Bhola P.D., Letai A. Mitochondria-judges and executioners of cell death sentences //
Mol Cell. 2016. N. 61. P. 695–704.
117. Bischo E.W., Hamd D.H., Sedeno M. et al. Eects of written action plan adherence
on COPD exacerbation recovery // orax. 2011. Vol. 66. P. 26–31.
118. Blackstock F.C., Evans R.A. Rehabilitation in lung diseases: Education component
of pulmonary rehabilitation // Respirology. 2019. Vol. 24, N. 9. P. 863–870.
119. Brassington K., Selemidis S., Bozinovski S. et al. New frontiers in the treatment of
comorbid cardiovascular disease in chronic obstructive pulmonary disease // Clin
Sci (Lond). 2019. Vol. 133, N 7. P. 885–904.
https://t.me/med1917
145
Список литературы
120. O’Brien K., Geddes E.L., Reid W.D. et al. Inspiratory muscle training compared
with other rehabilitation interventions in chronic obstructive pulmonary
disease: a systematic review update // J Cardiopulm Rehabil Prev. 2008. Vol. 28.
P. 128–141.
121.
Brindle P., Emberson J., Lample F. et al. Predictive accuracy of the Framingham
Coronary Risk Score in British Men: prospective cohort study // BMJ. 2003.
Vol. 327. P. 1267–1270.
122. Brodskaya T., Nevzorova V., Za kharchuk N. et al. Aortic stiness and polymorphisms
of collagen-1 type 1a gene in COPD patients // J Lung Pulm Respir Res. 2018.
Vol. 5, N. 3. P. 81‒85.
123. Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol xed-dose
combination versus mono-components in COPD (GOLD 2–4) // Eur Respir J. 2015.
Vol. 45. P. 969–979.
124. 1o’Callaghan C. J., Williams B. Mechanical strain-induced extracellular matrix
production by human vascular smooth muscle cells: role of TGF-beta (1) //
Hypertension. 2000. Vol. 36, № 3. P. 319–324.
125. Calverley P.M.A., Anderson A.M.A., Ferguson G.T et al. Salmeterol and uticasone
propionate and survival in chronic obstructive pulmonary disease // N Engl J Med.
2007. Vol. 356. P. 775–789.
126.
Calverley P.M.A., Rabe K.F., Goehring U-M. et al. Roumilast in symptomatic
chronic obstructive pulmonary disease: two randomised clinical trials // Lancet.
2009. Vol. 374. P. 685–694.
127.
McCarthy B., Casey D., Devane D. et al. Pulmonary rehabilitation for chronic
obstructive pulmonary disease // Cochrane Database Syst Rev. 2015. Vol. 2, N. 2.
CD003793.
128. 1Casaburi R., Kukaa D., Cooper C.B. et al. Improvement of exercise tolerance
with combination of tiotropium and pulmonary rehabilitation in patients with
COPD // Chest. 2005. Vol. 127, N. 3. P. 809–817.
129.
Cazzola M., Calzetta L., Page C. et al. Inuence of N-acetylcysteine on chronic
bronchitis or COPD exacerbations: a meta-analysis // Eur Respir Rev. 2015. Vol. 24,
N. 137. P. 451–461.
130. 1Cazzola M., Matera M.G., Donner C.F. Inhaled beta2-adrenoceptor agonists:
cardiovascular safety in patients with obstructive lung disease // Drug. 2005.
Vol. 65, 12. P. 1595–1610.
131. Cazzola M., Noschese P., D’Amato G. et al. e pharmacologic treatment of
uncomplicated arterial hypertension in patients with airway dysfunction // Chest.
2002. Vol. 121. P. 230–241.
132. Chandler M.A., Rennard S.I. Smoking cessation // Chest. 2010. Vol. 137. P. 428–435.
https://t.me/med1917
146
Список литературы
133. Chatterjee S.S. e cardioselective and hypotensive eects of bisoprolol in
hypertensive asthmatics // J Cardiovasc Pharmacol. 1986. Vol. 8 (Suppl. 11).
S 74–S77.
134.
Chen L., Einbinder E., Zhang Q. et al. Oxidative stress and le ventricular function
with chronic intermittent hypoxia in rats // Am J Respir Crit Care Med. 2005.
Vol. 172, № 7. P. 915–920.
135.
1Chiu C.Z., Wang B.W., Shyu K.G. Molecular regulation of the expression of leptin
by hypoxia in human coronary artery smooth muscle cells // J. Biomed. Sci. 2015.
Vol. 22. N. 5.
136. Choi E.T., Collins E.T., Marine L.A. et al. Matrix metalloproteinase-9 modulation by
resident arterial cells is responsible for injury-induced accelerated atherosclerotic
plaque development in apolipoprotein E-decient mice // Arterioscler romb
Vasc Biol. 2005. V. 25. P. 1020–1025.
137.
Chong J., Poole P., Leung B. Et al. Phosphodiesterase 4 inhibitors for chronic
obstructive pulmonary disease // Cochrane Database Syst Rev. 2011. Vol. 5.
CD002309.
138. Christiani D.C. Vaping-Induced Lung Injury // N Engl J Med. 2020. Vol. 382, N. 10.
P. 960–962.
139.
Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and
risk factors in 12 regions of the Russian Federation // Int J COPD. 2014. Vol. 12. P.
963–974.
140. Chung V.C.H., Ma P.H.X., Hui D.S.C. et al. Indacaterol for chronic obstructive
pulmonary disease: systematic review and meta-analysis // PLoS ONE. 2013.
Vol. 8. e70784.
141. Cloonan S.M., Choi A.M. Mitochondria in lung disease // J Clin Invest. 2016.
N. 126. P. 809–820.
142. Cockcro J.R., Pedersen M.E. b-blockade: benets beyond blood pressure
reduction? // J Clin Hypertens (Greenwich). 2012. Vol. 14, N. 2. P. 112–120.
143. Colditz G.A., Bonita R., Stampfer M.J. et al. Cigarette smoking and risk of stroke in
middle-aged women // N. Engl. J. Med. 1988. Vol. 318. P. 937–941.
144.
Collier P., Phelan D., Klein A. A Test in Context: Myocardial Strain Measured
by Speckle-Tracking Echocardiography // J Am Coll Cardiol. 2016. Vol. 69, N. 8.
P.1043-1056.
145. COPD Working Group. Pulmonary Rehabilitation for Patients With Chronic
Pulmonary Disease (COPD): An Evidence-Based Analysis // Ont Health Technol
Assess Ser. 2012. Vol. 12, N. 6. P. 1–75.
146. Costanzo L., Pedone C., Battistoni F. Relationship between FEV1 and arterial
stiness in elderly people with chronic obstructive pulmonary disease // Aging.
Clin. Exp. Res. 2017. Vol. 29, № 2. P. 157–164.
https://t.me/med1917
147
Список литературы
147. COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor
blockers. Scientic Brief 7 May 2020. Geneva: World Health Organization;
2020.
148.
Cox N.S., Dal Corso S., Hansen H. et al. Telerehabilitation for chronic respiratory
disease // Cochrane Database Syst Rev. 2021. Vol. 1, N. 1. Cd013040.
149.
Cruz-Lemini M., Crispi F., Valenzuela-Alcaraz B. et al. A fetal cardiovascular score
to predict infant hypertension and arterial remodeling in intrauterine growth
restriction // AJOG. 2014. Vol. 210. № 6. P. 552.e1–552.e22.
150. Curkendall S.M., DeLuise C., Jones J.K. et al. Cardiovascular disease in patients
with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular
disease in COPD patients // Ann Epidemiol. 2006. Vol. 16, № 1. P. 63–70.
151. Dahl M., Bowler R. P., Juul K. et al. Superoxide dismutase 3 polymorphism
associated with reduced lung function in two large populations // Am J Respir Crit
Care Med. 2008. Vol. 178, № 9. P. 906–912.
152. Dal Negro R. Pulmonary eects of nebivolol // er Adv Cardiovasc Dis. 2009.
Vol. 3, N. 4. P. 329–334.
153.
Decramer M., Anzueto A., Kerwin E. et al. Ecacy and safety of umeclidinium
plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over
24 weeks in patients with chronic obstructive pulmonary disease: results from two
multicenter, blinded, randomized controlled trials // Lancet Respir Med. 2014.
Vol. 2. P. 472–486.
154.
Decramer M., Celli B., Kesten S. et al. Eect of tiotropium on outcomes in patients
with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecied
subgroup analysis of a randomised controlled trial // Lancet 2009. Vol. 374.
P. 1171–1178.
155.
Decramer M.L., Chapman K.R., Dahl R. et al. INVIGORATE investigators. Once-
daily indacaterol versus tiotropium for patients with severe chronic obstructive
pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group
study // Lancet Respir Med. 2013. Vol. 1, N. 7. P.524–533.
156. Dekhuijzen P. N., Aben K. K., Dekker I. Increased exhalation of hydrogen peroxide
in patients with stable and unstable chronic obstructive pulmonary disease //
Am J Respir Crit Care Med. 1996. Vol. 154, № 3, Pt. 1. P. 813–816.
157. De Marco R., Accordini S., Cerveri I. et al. Incidence of chronic obstructive
pulmonary disease in a cohort of young adults according to the presence of chronic
cough and phlegm // Am J Respir Crit Care Med. 2007. Vol. 175. P. 32–39.
158. De Marco R., Accordini S., Marcon A. et al. European Community Respiratory
Health Survey (ECRHS): Risk factors for chronic obstructive pulmonary disease
in a European cohort of young adults // Am J Respir Crit Care Med. 2011. Vol. 183.
P. 891–897
https://t.me/med1917
148
Список литературы
159. Diette G.B., Rand C.S., Wise R.A et al. Feasibility of using a sham control device
in clinical trials of High frequency Chest wall Oscillation (HFCWO) in COPD //
Am J Respir Crit Care Med. 2004. Vol. 167. P. 613.
160.
Divo M., Cote C., de Torres J.P. et al. Comorbidities and risk of mortality in patients
with chronic obstructive pulmonary disease // Am J Respir Crit Care Med. 2012.
Vol. 186, N 2. P. 155–161.
161.
Donath E., Chaudhry A., Hernandez-Aya L.F. et al. A metaanalysis on the
prophylactic use of macrolide antibiotics for the prevention of disease exacerbations
in patients with chronic obstructive pulmonary disease // Respir Med. 2013.
Vol. 107. P. 1385–1392.
162.
o’Donnell M.J., Xavier D., Liu L. et al. Risk factors for ischaemic and intracerebral
haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control
study // Lancet. 2010. Vol. 376, № 9735. P. 112–123.
163. Donohue J.F., Maleki-Yazdi M.R., Kilbride S. et al. Ecacy and safety of once-
daily umeclidinium/vilanterol 62.5/25 mcg in COPD // Respir Med. 2013. Vol. 107.
P. 1538–1546.
164. Dorow P., Bethge H., Tönnesmann U. Eects of single oral doses of bisoprolol and
atenolol on airway function in nonasthmatic chronic obstructive lung disease and
angina pectoris // Eur J Clin Pharmacol. 1986. Vol. 31, N. 2. P. 143–147.
165.
Dugac A.V., Ruzic A., Samarzija M. et al. Persistent endothelial dysfunction turns
the frequent exacerbator COPD from respiratory disorder into a progressive
pulmonary and systemic vascular disease // Medical Hypotheses. 2015. Vol. 84,
N 2. P. 155–158.
166. Duong C., Seow H. J., Bozinovski S. et al. Glutathione peroxidase-1 protects against
cigarette smoke-induced lung inammation in mice // Am J Physiol Lung Cell Mol
Physiol. 2010. Vol. 299, № 3. P. L425–L433.
167. Durmowicz A. G., Stenmark K. R. Mechanisms of structural remodeling in chronic
pulmonary hypertension // Pediatr Rev. 1999. Vol. 20, № 11. P. e91–e102.
168. Earley S., Nelin L. D., Chicoine G. et al. Hypoxia-induced pulmonary endothelin-1
expression is unaltered by nitric oxide // J Appl Physiol. 2002. Vol. 92, № 3. P. 1152–1158.
169.
Eng T.W., Vercoulen J.H., Bourbeau J. et al. Denition of a COPD self-management
intervention: International Expert Group consensus // Eur Respir J. 2016. Vol. 48,
N. 1. P. 46–54.
170. Egred M., Shaw S., Mohammad B. et al. Under-use of beta-blockers in patients with
ischaemic heart disease and concomitant chronic obstructive pulmonary disease //
QJM. 2005. Vol. 98, 7. P. 493–497.
171. Ekström M.P., Hermansson A.B., Ström K.E. Eects of cardiovascular drugs on
mortality in severe chronic obstructive pulmonary disease // Am J Respir Crit Care
Med. 2013. Vol. 187, N. 7. P. 715–720.
https://t.me/med1917
149
Список литературы
172. Eller J., Ede A., Schaberg T. et al. Infective exacerbations of chronic bronchitis:
relation between bacteriologic etiologyand lung function // Chest. 1998. Vol. 113.
P. 1542–1548.
173.
McEniery Yasmin C.M., Wallace S., Mackenzie I.S. et al. C-reactive protein is
associated with arterial stiness in apparently healthy individuals // Arterioscler.
romb. Vasc. Biol. 2004. Vol. 24, № 5. P. 969–974.
174.
Epstein S., A.C. Vergnaud A.C., Elliott P. et al. Numerical assessment of the stiness
index // Conf Proc IEEE Eng Med Biol Soc. 2014. № 2014. Р. 1969-1972.
175.
Estruch R., Ros E., Salas-Salvado J. et al. PREDIMED Study Investigators. Primary
prevention of cardiovascular disease with a Mediterranean diet // N Engl J Med.
2013. Vol. 368. P. 1279–1290.
176. Ettehad D., Emdin C.A., Kiran A. et al. Blood pressure lowering for prevention of
cardiovascular disease and death: a systematic review and meta-analysis // Lancet
2016. Vol. 387. P. 957–967.
177. Fabbri L.M., Luppi F., Beghe B. et al. Complex chronic comorbidities of COPD //
Eur Respir J. 2008. Vol. 31, N 1. P. 204–212.
178.
Fan V.S., Gaziano J.M., Lew R. et al. A comprehensive care management program
to prevent chronic obstructive pulmonary disease hospitalizations: a randomized,
controlled trial // Ann Intern Med. 2012. Vol. 156, N. 10. P. 673–683.
179.
Faner R., Tal-Singer R., Riley J.H. et al. Lessons from ECLIPSE: a review of COPD
biomarker // orax. 2014. Vol. 69, № 7. P. 666–672.
180.
Farand P., Garon A., Plante G. E. et al. Structure of large arteries: orientation of
elastin in rabbit aortic internal elastic lamina and in the elastic lamellae of aortic
media // Microvasc. Res. 2007. Vol. 73, № 2. P. 95–99.
181. Farsang C.K., Kiss I., Tykarski A. et al. Narkiewicz K. Treatment of hypertension
in patients with chronic obstructive pulmonary disease (COPD) // Eur Soc
Hypertension Sci Newsletter. 2016. Vol. 17. P. 62.
182. Fiore M.C., Bailey W.C., Cohen S.J. et al. e tobacco use and dependence clinical
practice guideline panels, and consortium representatives. A clinical practice guideline
for treating tobacco use and dependence // JAMA. 2000. Vol. 28. P. 3244–3254.
183. Fiore M., Jaen C.R., Baker T.B. et al. A clinical practice guideline for treating
tobacco use and dependence: 2008 update. A U.S. Public Health Service report //
Am J Preventive Med. 2008. Vol. 35, N. 2. P. 158–176.
184. Flegal K.M., Kit B.K., Orpana H. et al. Association of all-cause mortality with
overweight and obesity using standard body mass index categories: a systematic
review and meta-analysis // JAMA. 2013. Vol. 309. P. 71–78.
185. Furchgott R.F., Zawadzki J.V. e obligatory role of endothelial cells in the
relaxation of arterial smooth muscle by acetylcholine // Nature. 1980. Vоl. 288.
N. 5789. P. 373-376.
https://t.me/med1917
150
Список литературы
186. Galderisi M., Cosyns B., Edvardsen T. et al. Standardization of adult transthoracic
echocardiography reporting in agreement with recent chamber quantication,
diastolic function, and heart valve disease recommendations: an expert consensus
document of the European Association of Cardiovascular Imaging //Eur Heart
J Cardiovasc Imaging. 2017. Vol. 18, N. 12. P. 1301‐1310.
187.
Galie N., McLaughlin V.V., Rubin L.J. et al. An overview of the 6th World Symposium
on Pulmonary Hypertension // Eur Respir J. 2019. Vol. 53, N. 1.
188.
Garvey C., Bayles M.P., Hamm L.F. et al. Pulmonary Rehabilitation Exercise
Prescription in Chronic Obstructive Pulmonary Disease: Review of Selected
Guidelines: An ocial statement from the American Association of Cardiovascular
and Pulmonary Rehabilitation // J Cardiopulm Rehabil Prev. 2016. Vol. 36, N. 2.
P. 75–83.
189.
McGavin C.R., Williams I.P. e eects of oral propranolol and metoprolol on lung
function and exercise performance in chronic airways obstruction // Br J Dis Chest.
1978. Vol. 72, 4. P. 327–332.
190. Gea J., Pascual S., Casadevall C. et al. Muscle dysfunction in chronic obstructive
pulmonary disease: update on causes and biological ndingsm // J orac Dis. 2015.
Vol. 7, № 10. P. e418–e438.
191. Gibbons Н.Н., Dzau V.J. e emerging concept of vascular remodeling // N Engl
J Med. 1994. N. 330. P. 1431-1438.
192.
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the
Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary
Disease. Revised. 2022. http://www.goldcopd.com.
193.
Goettsch C., Rauner M., Hamann C. et al. Nuclear factor of activated T cells
mediates oxidised LDL-induced calcication of vascular smooth muscle cells //
Diabetologia. 2011. Vol. 54. P. 2690–701.
194. Golpe R., Sanjuán-López P., Martín-Robles I. et al. Cardiovascular studies in
patients with chronic obstructive pulmonary disease due to biomass smoke or
tobacco // Lung. 2018. Vol. 196, № 2. P. 195–200.
195. Goncalves J., Sanchez R. et al. Cardiovascular comorbidity in patients with chronic
obstructive pulmonary disease in the Canary Islands (CCECAN study) // J Clin
Investig Arteriosclerosis. 2017. Vol. 29, N 4. P. 149–156.
196. Gordon C., Gudi K., Krause A. et al. Circulating endothelial microparticles as a
measure of early lung destruction in cigarette smokers // Am. J. Respir. Crit. Care
Med. 2011. Vol. 184, № 2. P. 224–232.
197. Gottlieb S.S., McCarter R.J., Vogel R.A. Eect of beta-blockade on mortality among
high-risk and low-risk patients aer myocardial infarction // N Engl J Med. 1998.
Vol. 339, 8. P. 489–497.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана